|By PR Newswire||
|September 28, 2012 02:01 AM EDT||
REDWOOD CITY, California and VIENNA, Austria, September 28, 2012 /PRNewswire/ --
Large Prospective Study Validates Use of the Oncotype DX test in Stage II and Stage III Colon Cancer and Identifies Genes that May Indicate Effectiveness of Oxaliplatin
Results from Europe and Mexico-Based Studies Reconfirm the Impact of the Oncotype DX test on Guiding Treatment Decisions in Invasive Breast Cancer Patients
Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of data that support expanded use of the Oncotype DX® tests in optimising treatment decisions for breast and colon patients at various stages of disease. The new data confirm the ability of the Oncotype DX colon cancer test to predict recurrence risk in stage II and stage III colon cancer patients, and exploratory analyses have identified 16 genes strongly associated with oxaliplatin treatment benefit. Additionally, two studies reconfirm the clinical utility of the Oncotype DX breast cancer test in treatment decision making in women with early-stage invasive breast cancer.
The study results are being presented at the 2012 European Society for Medical Oncology (ESMO) Congress taking place September 28-October 2 in Vienna, Austria.
"Personalised medicine requires accurate assessment of the patient's individual tumor biology," said Christer Svedman, director, medical affairs in Europe, Genomic Health. "The new data add to a large body of evidence demonstrating that the Oncotype DX test is an important tool enabling more informed treatment decisions in early-stage breast and colon cancer patients worldwide."
Colon Cancer: Findings Provide Third Successful Prospectively Designed Study of Oncotype DX Colon Cancer Test in Patients with Stage II Disease, First Validation Study in Patients with Stage III Disease; Identify Genes that May Predict Patient Benefit from Oxaliplatin
A large, independent validation study involving 892 patients demonstrates that the Oncotype DX Colon Cancer Recurrence Score® results predict risk of recurrence, disease-free survival and overall survival in stage II and stage III colon cancer patients receiving adjuvant chemotherapy in the landmark randomised NSABP C-07 clinical trial. The study also indicates that risk assessment with the Recurrence Score assay enables better discrimination of the expected absolute benefit of adding oxaliplatin to adjuvant 5FU chemotherapy.
Additionally, an exploratory component of this study, researchers analysed 735 genes and identified 16 genes as being predictive of oxaliplatin benefit, narrowing down specific genes and pathways associated with sensitivity or resistance to oxaliplatin when added to adjuvant 5-fluorouracil chemotherapy. The company will utilize these positive results to develop an algorithm and a standardised quantitative laboratory process with the plan to initiate a validation study in 2013.
"The Recurrence Score has shown us that there is a continuous biology in colon cancer versus a high or low ranking, and understanding where a patient falls on that continuum is going to help both stage II and stage III colon cancer patients make more informed decisions regarding adjuvant therapy," said principal investigator Michael O'Connell, M.D., associate chairman of The National Surgical Adjuvant Breast and Bowel Project (NSABP). "The discovery of new genes holds promise for the development of a genomic test that would benefit a broader Stage II and Stage III patient population by providing better understanding of oxaliplatin benefit."
The poster and discussion presentation titled, "The 12-gene Colon Cancer Recurrence Score (RS) Predicts Recurrence in Stage II and III Colon cancer Patients Treated with 5FU/LV (FU) and 5FU/LV + Oxaliplatin (FU+Ox): Validation in NSABP C-07" (Abstract #523PD), will take place on Sept. 29, 1-2 p.m., Hall C.
Breast Cancer: Growing Evidence Continues to Reinforce the Impact of the Oncotype DX test on Treatment Decisions in Patients with Early-Stage Invasive Breast Cancer
"Genomic testing reveals the patient's individual tumor biology, enabling more informed treatment decisions," said Simon Holt, MA, MB, BChir, FRCS, Lead Breast Surgeon, Hywel Dda Health Board, Wales, United Kingdom. "Oncotype DX is the only clinically validated multi-gene assay that has proved predictive of chemotherapy treatment benefit and new data reinforces the important role this test can play in ultimately enhancing the quality of care for breast cancer patients."
- A meta-analysis of four prospective studies from the United Kingdom, Germany, France, and Spain including 565 patients with node-negative, estrogen receptor-positive breast cancer, showed that based on knowledge of the Recurrence Score result, 48 percent of patients initially recommended chemotherapy were advised to omit chemotherapy and 18 percent of patient who were initially advised hormonal therapy alone were advised to add chemotherapy. These results further demonstrate that use of the Oncotype DX test is associated with a significant change in treatment decisions and an overall reduction in chemotherapy use in the studied European countries regardless of different local treatment traditions.
The poster and discussion titled, "Meta-analysis of Prospective European Studies Assessing the Impact of Using the 21-Gene Recurrence Score Assay on Clinical Decision Making in Women with ER-positive, HER2-negative Early Stage Breast Cancer" (Abstract #252PD), will take place on Sept. 29, 1-2 p.m., Hall G.
- Results of the first Oncotype DX breast cancer test treatment decision impact study from Mexico showed that in 96 patients who used the test in a public hospital setting, the knowledge of the Recurrence Score result changed physicians' treatment recommendations for 32 percent of early-stage invasive breast cancer patients. This study demonstrated that, based on the Recurrence Score result, 46 percent of patients initially recommended chemotherapy were advised to omit chemotherapy and use hormonal therapy alone, and 16 percent of patients initially recommended hormonal therapy alone were advised to add chemotherapy to their treatment regimen. These results suggest that use of the Oncotype DX test in the Mexican public health system has an impact on adjuvant treatment recommendations and may reduce the need and use of chemotherapy.
The poster presentation titled, "A study of the impact of the 21-gene breast cancer assay on the use of adjuvant chemotherapy in women with breast cancer in a Mexican public hospital" (Abstract #289P), will take place on Oct. 1, 1-2 p.m., Hall XL.
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is a global health company that provides actionable genomic information to personalize genomic health decisions. The company's lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease. As of June 30, 2012, more than 10,000 physicians in over 65 countries had ordered more than 295,000 Oncotype DX tests. Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional treatment decisions in breast and colon cancers. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland. For more information, please visit, http://www.GenomicHealth.com. To learn more about Oncotype DX tests, visit: http://www.OncotypeDX.com and http://www.mybreastcancertreatment.org.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the ability of the Company's tests to optimize cancer treatment in patients with breast and colon cancer; the ability of the Oncotype DX Breast Cancer test Recurrence Score to impact treatment decisions in a clinical setting; the ability of the Oncotype DX Colon Cancer test to individualize cancer treatment decisions stage II and III colon cancer patients treated with Oxaliplatin; the potential of the Company's tests to change medical practice ; the applicability of study results to clinical practice; the timing and results of future studies; the focus of the company's product pipeline, the ability of the company to develop additional tests in the future , and the ability of any potential tests the company may develop to optimize cancer treatment. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the applicability of clinical study results to actual outcomes; the risks and uncertainties associated with possible additional regulation of our tests both in the United States and abroad; the risks associated with the commercialization of current and future products; the risks associated with competition; the risks and potential delays associated with such studies; unanticipated costs or delays in research and development efforts; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2012. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
A completely new computing platform is on the horizon. They’re called Microservers by some, ARM Servers by others, and sometimes even ARM-based Servers. No matter what you call them, Microservers will have a huge impact on the data center and on server computing in general. Although few people are familiar with Microservers today, their impact will be felt very soon. This is a new category of computing platform that is available today and is predicted to have triple-digit growth rates for some ...
Oct. 28, 2016 02:00 AM EDT Reads: 34,350
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
Oct. 28, 2016 02:00 AM EDT Reads: 4,376
As the world moves toward more DevOps and Microservices, application deployment to the cloud ought to become a lot simpler. The Microservices architecture, which is the basis of many new age distributed systems such as OpenStack, NetFlix and so on, is at the heart of Cloud Foundry - a complete developer-oriented Platform as a Service (PaaS) that is IaaS agnostic and supports vCloud, OpenStack and AWS. Serverless computing is revolutionizing computing. In his session at 19th Cloud Expo, Raghav...
Oct. 28, 2016 01:15 AM EDT Reads: 2,221
In past @ThingsExpo presentations, Joseph di Paolantonio has explored how various Internet of Things (IoT) and data management and analytics (DMA) solution spaces will come together as sensor analytics ecosystems. This year, in his session at @ThingsExpo, Joseph di Paolantonio from DataArchon, will be adding the numerous Transportation areas, from autonomous vehicles to “Uber for containers.” While IoT data in any one area of Transportation will have a huge impact in that area, combining sensor...
Oct. 28, 2016 01:00 AM EDT Reads: 1,202
SYS-CON Events announced today that Transparent Cloud Computing (T-Cloud) Consortium will exhibit at the 19th International Cloud Expo®, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. The Transparent Cloud Computing Consortium (T-Cloud Consortium) will conduct research activities into changes in the computing model as a result of collaboration between "device" and "cloud" and the creation of new value and markets through organic data proces...
Oct. 28, 2016 12:45 AM EDT Reads: 1,515
So you think you are a DevOps warrior, huh? Put your money (not really, it’s free) where your metrics are and prove it by taking The Ultimate DevOps Geek Quiz Challenge, sponsored by DevOps Summit. Battle through the set of tough questions created by industry thought leaders to earn your bragging rights and win some cool prizes.
Oct. 28, 2016 12:45 AM EDT Reads: 4,260
Between the mockups and specs produced by analysts, and resulting applications built by developers, there exists a gulf where projects fail, costs spiral, and applications disappoint. Methodologies like Agile attempt to address this with intensified communication, with partial success but many limitations. In his session at @DevOpsSummit at 19th Cloud Expo, Charles Kendrick, CTO at Isomorphic Software, will present a revolutionary model enabled by new technologies. Learn how business and deve...
Oct. 28, 2016 12:15 AM EDT Reads: 1,614
Enterprises have been using both Big Data and virtualization for years. Until recently, however, most enterprises have not combined the two. Big Data's demands for higher levels of performance, the ability to control quality-of-service (QoS), and the ability to adhere to SLAs have kept it on bare metal, apart from the modern data center cloud. With recent technology innovations, we've seen the advantages of bare metal erode to such a degree that the enhanced flexibility and reduced costs that cl...
Oct. 28, 2016 12:00 AM EDT Reads: 631
SYS-CON Events announced today that Niagara Networks will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.
Oct. 28, 2016 12:00 AM EDT Reads: 1,452
In his session at Cloud Expo, Robert Cohen, an economist and senior fellow at the Economic Strategy Institute, will provide economic scenarios that describe how the rapid adoption of software-defined everything including cloud services, SDDC and open networking will change GDP, industry growth, productivity and jobs. This session will also include a drill down for several industries such as finance, social media, cloud service providers and pharmaceuticals.
Oct. 28, 2016 12:00 AM EDT Reads: 2,183
Everyone knows that truly innovative companies learn as they go along, pushing boundaries in response to market changes and demands. What's more of a mystery is how to balance innovation on a fresh platform built from scratch with the legacy tech stack, product suite and customers that continue to serve as the business' foundation. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, will discuss why and how ReadyTalk diverted from healthy revenue an...
Oct. 27, 2016 10:30 PM EDT Reads: 3,084
SYS-CON Media announced today that @WebRTCSummit Blog, the largest WebRTC resource in the world, has been launched. @WebRTCSummit Blog offers top articles, news stories, and blog posts from the world's well-known experts and guarantees better exposure for its authors than any other publication. @WebRTCSummit Blog can be bookmarked ▸ Here @WebRTCSummit conference site can be bookmarked ▸ Here
Oct. 27, 2016 10:30 PM EDT Reads: 9,808
Intelligent machines are here. Robots, self-driving cars, drones, bots and many IoT devices are becoming smarter with Machine Learning. In her session at @ThingsExpo, Sudha Jamthe, CEO of IoTDisruptions.com, will discuss the next wave of business disruption at the junction of IoT and AI, impacting many industries and set to change our lives, work and world as we know it.
Oct. 27, 2016 10:30 PM EDT Reads: 553
In today's uber-connected, consumer-centric, cloud-enabled, insights-driven, multi-device, global world, the focus of solutions has shifted from the product that is sold to the person who is buying the product or service. Enterprises have rebranded their business around the consumers of their products. The buyer is the person and the focus is not on the offering. The person is connected through multiple devices, wearables, at home, on the road, and in multiple locations, sometimes simultaneously...
Oct. 27, 2016 10:30 PM EDT Reads: 3,840
Established in 1998, Calsoft is a leading software product engineering Services Company specializing in Storage, Networking, Virtualization and Cloud business verticals. Calsoft provides End-to-End Product Development, Quality Assurance Sustenance, Solution Engineering and Professional Services expertise to assist customers in achieving their product development and business goals. The company's deep domain knowledge of Storage, Virtualization, Networking and Cloud verticals helps in delivering ...
Oct. 27, 2016 10:15 PM EDT Reads: 1,163